Basic & Clinical Cancer Research 2017. 9(4):4-12.

Changes Of CEA and CA15-3 Biomarkers in the Breast Cancer Patients following eight Weeks of Aerobic Exercise
Azar Esfahbodi, Mehrdad Fathi, Gholam Rasul Mohammad Rahimi

Abstract


Background:Physical activity has beneficial effects on the elderly susceptible to the development of cancers, through maintaining a healthy body condition and improving the state of disease. In the present study, we investigated the variation of cancer-related biomarkers, such as Carcinoembryonic Antigen (CEA) and Cancer Antigen 15-3 (CA 15-3) following eight weeks of aerobic exercise in middle-aged women with breast cancer.

Methods: In this quasi-experimental study, 15 females with breast cancer with mean age (44.46±17.15 years of age), weight (70.53±5.18 kg) and body mass index (27.58±2.18 kg/m2) were selected and considered as the experimental group. The exercise program consisted of 8 weeks of aerobic exercise; three sessions per week for 40-60 minutes and with an intensity of 30%-60% heart rate reserve (HRR). Before and after the experiment, while all patients were fasting for 12 hours and did not have any vigorous physical activity for 24 hours, the level of CEA and CA15-3 was measured. Data were analyzed by paired sample t-test at a significance level of P<0.05.

Results:Findings showed that the tumor markers (CEA and CA15-3) levels did not change significantly after 8 weeks of aerobic exercise (P=0.542 and P=0.091); while there was a significant decrease (p=0/001) in body mass index, body fat percentage and weight in middle-aged women with breast cancer‎.

Conclusion: We suggest that exercise for 3 days per week improves body composition indices, without increasing the level of fatigue or stress values, which may contribute to prevent cancer prevalence in elderly women.


Keywords


Exercise; Carcinoembryonic Antigen; Cancer Antigen 15-3; Women; Breast Cancer

Full Text:

PDF

References


Guarneri V, Conte P. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging.2004; 31:149-56.

Taleghani F, Yekta ZP, Nasrabadi AN. Coping with breast cancer in newly diagnosed Iranian women. J Adv Nurs.2006; 54:265-72.

Lonning PE. Breast cancer prognostication and prediction: are we making progress? Ann Oncol.2007; 18: 3–7.

Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet.2011; 37:1812–1823.

Valenzuela P. The contribution of CEA marker to CA15-3 in the follow up of breast cancer. Eur J Gynaecol Oncol.2003; 24: 60-62.

Hashemi E, Montazeri A, Akbari ME, Njafi M, Haghighi SH, Kaviani A. Role of tumor markers in breast cancer recurrence.J Guilan University Med Sci.2014; 14: 28-32.

Incoronato M, Mirabelli P, Catalano O, Aiello M, Parente C, Soricelli A et al. CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients. BMC Cancer.2014; 1:356-61.

Lee JS, Park S, Park JM, Cho JH, Kim SI, Park BW. Elevated levels of preoperative CA 15–3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol.2013; 24:1225–1231.

Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med.1965; 121:439e62.

Nishimura R. Elevated serum CA15-3 level correlate with positive estrogen receptor and initial favorable outcome in patients who Die from recurrent breast cancer. Breast Cancer.2000; 10: 220-227.

Roy LD, Sahraei M, Subramani DB et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene.2011; 30: 1449–59.

Ganguly, A., Yeltsin, E. & Robbins, J. Identification of a carcinoembryonic antigen binding protein on monocytes. Biochem. Biophys. Res. Commun.2003; 311: 319-23.

Aarons, C.B., Bajenova, O., Andrews, C., Heydrick, S., Bushell, K.N., Reed, K.L., Thomas, P., Becker, J.M. et al. Carcinoembryonic antigen-stimulated THP-1 macrophages activate endothelial cells and increase cell-cell adhesion of colorectal cancer cells. Clin. Exp. Metastasis.2007; 24: 201-209.

Karimi Z, Houshiar-rad A, Mirzayi H, B. R. Dietary Patterns and Breast Cancer Among Women. Iranian Journal of Endocrinology and Metabolism.2011; 14:53-63.

Noori R, Damirchi A, Rahmani-nia F, N. R. The Effects of Combined Exercise Training on Some Anthropometric Variables in Postmenopausal Women with Breast Cancer. J of sport Bio.2010; 2:77-90.

Esfahbodi A, Fathie M, Moazami M, Mohammad Rahimi GH R. The Effect of Aerobic Training on the Level of Growth Hormone and 17-beta Estradiol Middle-aged Women with Breast Cancer.Armaghane-danesh.2016; 21: 563-75.

Porock D, kristjanson L, Tinnelly K. An exercise Intervention for Advanced Cancer Patients Experiencing Fatigue: a Pilot Study. Jornal of Paliative Care.2000; 16: 30-6.

Kolden GG, Strauman TJ, Ward A, Kuta J, Woods TE, Schneider KL, et al. A pilot study of group exercise training (GET) for women with primary breast cancer: feasibility and health benefits. Psychooncology.2002; 11: 447-56.

Kheyrdeh M, Daryanoosh F, Sadeghi Poor H.R, Khoshneshin Ghashghayi Z, Salesi M. Effects of an Eight-Week Aerobic Training on CA15-3 Marker,Growth Hormon and Insulin of Middle-Aged Women with Breast Cancer. Journal of Research in Exercise Biologycal Sciences. 2014; 3: 88-96.

Il-Gyu Ko, Eung-Mi Park, Hye-Jung Choi, Jaehyun Yoo, Jong-Kyun Lee and Yong-Seok Jee. Proper Exercise Decreases Plasma Carcinoembryonic Antigen Levels with the Improvement of Body Condition in Elderly Women. Tohoku J. Exp. Med.2014; 233: 17-23.

Alberti KGMM, Zimmet Pf. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine. 1998; 15:539-53.

Kurebayashi J, Nishimura R, Tanaka K, et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer. 2004; 11: 389-95.

Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem. 2002; 48: 1151-9.

Vyzula R, Dusek L, Zaloudik J, Demlova R, Klimes D, and Selvekerova S. Breast cancer and neoadjuvant therapy: any predictive marker? Neoplasma. 2004; 51:471-80.

Begic A, Krucukalic-Selimovic E,Obralic N et al. Role of bone scintigraphy and tumor marker CA15-3 in detection of bone metastases in patients with breast cancer. Bosn J Basic Med Sc. 2005; 5: 23-6.

Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem.2001; 34: 347-52.

Cengiz B, Atabekoglu C, Cetinkaya E and Cengiz SD. Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. Maturitas. 2003; 46: 301-06.

Pentheroudakis G, Malamou-Mitsi V, Briasoulis E, et al. The

neutrophil, not the tumor: serum CA15-3 elevation as a result of granulocyte-colonystimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy. Cancer .2004;101: 1767-75.

Kolden G, Strauman T J, Wrad A, Kuta J, Woods T E, Schneider K L. et al. A Pilot Study of Group Exercise Training (GET) for Women with Ptimary Breast Cancer: Feasibility and Health Benefits. Psycho – Oncology.2002; 11: 447–56.

Lee, I.M., Paffenbarger, R.S. Jr. & Hsieh, C.C. Physical activity and risk of prostatic cancer among college alumni. Am. J. Epidemio, .1992;135: 169-79.

Lee, J.W., Park, K.D., Im, J.A., Hwang, H.J. & Kim, S.H. Serum carcinoembryonic antigen is associated with metabolic syndrome in female Korean non-smokers. Clin. Chim. Acta .2011; 412: 527-30

Kobayashi, L.C., Janssen, I., Richardson, H., Lai, A.S., Spinelli, J.J. & Aronson, K.J. Moderate-to-vigorous intensity physical activity across the life course and risk of pre- and post-menopausal breast cancer. Breast Cancer Res. Treat. 2013; 139: 851-61.

Omidvari SH, Moslemi D, Larizadeh MH, Mosalaei A Mohamadian Panah M, Ah,adloo N. Sesitivy and specificity of CA15-3 in detection of breast cancer recurrence. Journal of Kerman University of Medical Sciences.2005; 12: 181-87.

Hammarstrom, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol, 1999; 9: 67-81.

Fukuda, I., Yamakado, M. & Kiyose, H. Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services. J. Med. Syst. 1998; 22: 89-93.

Ruibal Morell, A. CEA serum levels in non-neoplastic disease. Int. J. Biol. Markers. 1992;7: 160-66.

Carriquiry, L.A. & Pineyro, A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis. Colon Rectum. 1999; 42: 921-29.

Bast R C, Bates S, Bredt A B. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol. 1996;14:2843–77


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.